Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235 Estimated average burden hours per response... 3235-0287 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the

Investment Company Act of 1940

(Print or Ty	ype Response	es)														
Name and Address of Reporting Person * Cheong Kwang Soo				2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
		(First) ARMACEUTICA ER DRIVE	ALS, INC., 9620	3. Date of 06/30/2	of Ea 2008	rliest Tr	ansac	tion (Month/I	Day/Year)				e title below)		ner (specify belo	w)
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) X Form filed by One Reporting Person					
ROCKVILLE, MD 20850										Form filed by More than One Reporting Person						
(Ci	ty)	(State)	(Zip)			Ta	ble I	- Non-Deriva	tive Securiti	es Acqu	iired,	Disposed	of, or Ben	eficially Ow	ned	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea			2A. Deemed Execution Date, if any (Month/Day/Year)		Date, if	(Instr. 8)		4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5)		of (D) Owned Follow)		Ownership Form:	Beneficial Ownership	
							Code V		mount (A) or	Price	ice				(I) (Instr. 4)	,
p : 1	D (. 1. 6	1 1 6 '4'	1 6	- 11					1					(
Reminder	Report on a	separate line for eac	on class of securitie	s benefici	any	owned (illecti	Persons contain	s who respo ed in this fo splays a cur	rm are	not r	equired	to respor	nd unless t		474 (9-02)
									sed of, or Ben evertible secu		y Owi	ied				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year	Transaction of Deriv (Instr. 8) Secun (A) o Dispo (D) (Instr. 8)		Derivate Securit Acquire (A) or Dispos	exative rities aired or osed of 3, 4,				7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		Ownersh Form of Derivati Security Direct (I or Indire	(Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	:	Amount or Number of Shares				
Stock Options (right to buy)	\$ 1.20							05/01/200	7 05/01/201	n l	nmon ock	20,000		20,000	D	
Stock Options (right to buy)	\$ 1.40							06/11/2008	8 06/11/201	/	nmon ock	20,000		20,000	D	
Stock Options (right to buy)	\$ 3.24	06/30/2008		A		20,000	0	(1)	06/30/201	X I	nmon ock	20,000	\$ 0	20,000	D	
Repoi	rting O	wners								,						
R	Reporting Ov	wner Name / Addro	ess Direc	_		onships ner Off	ficer	Other								

Bonardin - Oroman Nama / Addings	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Cheong Kwang Soo C/O REXAHN PHARMACEUTICALS, INC. 9620 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850	X					

Signatures

/s/ Tae Heum Jeong attorney-in-fact for Cheong Kwang Soo	08/27/2008
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). (1) These options vest and become exercisable in full on June 30, 2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.